Value
4.1/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 4.1 |
| EV/EBITDA | 1.3 |
| p ocf | 7.0 |
| Analyst target | 4.0 |
- ▸P/OCF: 15.0x (FFO proxy — REITs gated off P/E)
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
National Health Investors is a healthcare REIT with strong 37% margins, excellent free cash flow conversion, and analyst upside potential, but two consecutive earnings misses, negative price momentum, and a dividend coverage concern limit near-term entry attractiveness.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
| Pillar | Expectation | Trend |
|---|---|---|
NHI generates 37% net margins, converts 140% of net income to free cash flow, and carries a Rule of 40 score of 49, reflecting a high-quality income-oriented REIT structure with durable cash generation relative to its healthcare facility portfolio. Quality breakdown | Free cash flow conversion remains above 120% of net income and operating margin stays above 30% over the next 12 months. | →Stable |
| CounterThe dividend coverage warning in the analysis indicates the distribution may not be fully supported by sustainable cash flows, suggesting the headline FCF quality may reflect timing rather than structural strength. | ||
NHI has missed earnings estimates in the 2 most recent quarters, with surprises of -10.5% and -5.2%, indicating that operating results are running below the level analysts expected when they set their forward estimates. Earnings | NHI returns to meeting or beating consensus earnings in the next 2 quarterly reports without a surprise worse than -5%. | →Stable |
| CounterREITs are commonly valued on funds from operations rather than GAAP earnings, and per-share FFO may show a different trend than the GAAP EPS comparisons recorded here. | ||
The stock's momentum score of 3.6 falls below the minimum acceptable threshold of 4.5, and while the 200-day moving average is still rising, the stock is trading below it — a pullback within an uptrend that has not yet confirmed reversal. Momentum breakdown | Price recovers above the 200-day moving average and momentum score rises above 4.5 within 6 months. | →Stable |
| CounterMACD is bullish and the 200-day MA slope is positive at +0.5%/30 days, suggesting the moving average divergence represents a temporary pullback rather than a deteriorating trend. | ||
Analysts carry positive sentiment on NHI with a news sentiment reading and upside to consensus price target, and the stock's free cash flow and operational quality rank favorably relative to healthcare REIT peers. Sentiment breakdown | Analyst consensus price target rises above $77 within 12 months, restoring at least 8% upside from current levels. | →Stable |
| CounterWith only 4.3% upside to current analyst consensus targets and declining revenue, the margin of safety for new investors is very thin. | ||
CounterThe dividend coverage warning in the analysis indicates the distribution may not be fully supported by sustainable cash flows, suggesting the headline FCF quality may reflect timing rather than structural strength.
CounterREITs are commonly valued on funds from operations rather than GAAP earnings, and per-share FFO may show a different trend than the GAAP EPS comparisons recorded here.
CounterMACD is bullish and the 200-day MA slope is positive at +0.5%/30 days, suggesting the moving average divergence represents a temporary pullback rather than a deteriorating trend.
CounterWith only 4.3% upside to current analyst consensus targets and declining revenue, the margin of safety for new investors is very thin.
| Component | Sub-score |
|---|---|
| P/S | 4.1 |
| EV/EBITDA | 1.3 |
| p ocf | 7.0 |
| Analyst target | 4.0 |
| Component | Sub-score |
|---|---|
| ROE | 3.3 |
| ROA | 2.9 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 2.4 |
| FCF quality | 9.7 |
| Moat | 4.6 |
| Rule of 40 | 8.1 |
| Piotroski F | 6.7 |
| Component | Sub-score |
|---|---|
| Rev growth | 1.9 |
| EPS growth | 4.9 |
| Component | Sub-score |
|---|---|
| RSI | 2.8 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 7.2 |
| Volume | 0.0 |
| Component | Sub-score |
|---|---|
| LLM sentiment | 8.0 |
| Analyst rating | 6.8 |
| Price target | 6.5 |
| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
| Component | Sub-score |
|---|---|
| value rank | 4.7 |
| quality rank | 7.3 |
| growth rank | 2.3 |
| Component | Sub-score |
|---|---|
| bollinger | 0.2 |
| support resistance | 1.3 |
| 52w position | 6.7 |
| gap | 6.0 |
| Component | Sub-score |
|---|---|
| short interest | 7.8 |
| days to cover | 6.2 |
| volatility | 6.2 |
| put call | 8.3 |
| implied vol | 4.6 |
| beta | 9.7 |
| debt equity | 5.1 |
| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 2.9 |
| dividend safety | 3.5 |
| news activity | 6.0 |
Multiple concerning factors. Consider reducing position.
L4:PATH_F_SELLSetupRECOVERY — Death cross but MACD improving, RSI 73
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — MCap $3.6B<$5B
The F-path SELL output reflects an overall score of 5.2 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Sentiment at 7.1) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:-0.4=NEGATIVE) reinforce the read. Current asymmetry R:R is -0.38 — supplementary context, not the trigger for this path.
The strongest dimensions are Sentiment at 7.1, Quality at 6.8, and Risk (lower is worse) at 6.8; the weakest are Growth at 3.4, Technical at 3.6, and Value at 4.1. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -0.38 and an engine sizing output of AVOID.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
Trip ifFree cash flow conversion falls below 100% of net income for 2 consecutive quarters or operating margin drops below 25%.
Trip ifEPS surprise falls below -15% in at least 2 of the next 3 quarters.
Trip ifPrice drops below $66.78 stop-loss level or 200-day moving average slope turns negative.
Trip ifAnalyst consensus price target declines below $68 or revenue declines more than 8% year-over-year.